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Background: Cell cycle regulatory pathway is a well-established pathway mainly dependent on cyclin-dependent
kinases (CDKs), which are regulated positively by cyclins and negatively by cyclin-dependent kinase inhibitors(CKIs).
Cyclin-dependent kinase 2 associate protein 1(CDK2-AP1) is a specific negative regulatory protein for CDK2, is important
in the cancer cell cycle. However, the function of CDK2-AP1 in breast cancer remains unclear. We designed therefore
explored the effects of CDK2-AP1 on breast cancer growth and its chemo-sensitivity.
Methods: Expression of CDK2-AP1, CDK2 and CyclinD1 in 209 cases of pathological specimens using IHC staining was
measured. Lost-of-function and Gain-of-function assays were used in vivo and in vitro relating to the specific role of
CDK2-AP1 in breast cancer. We analyzed in vivo and in vitro the impact of CDK2-AP1 on chemotherapy sensitivity in
breast cancer.
Results: The positive ratio of CDK2-AP1 expression was reduced successively in normal breast tissue, DCIS, invasive
breast cancer and relapsed breast cancer, however, with CDK2 and CyclinD1 it was suggested that CDK2-AP1 was
correlated closely with the tumorigenesis and progress, and might work as a tumor suppressor. After down-regulating
CDK2-AP1 in breast cancer cells, the cell cycle was accelerated and cell proliferation enhanced. The cell cycle was
arrested in G0/G1 phase and G2/M phase after up-regulating CDK2-AP1 in breast cancer cells, inhibiting cell
proliferation. The expression of CDK2 and CyclinD1 changed accordingly after downregulation or upregulation of
CDK2-AP1 by western blot, suggesting a role of the CDK2-AP1/CDK2/CyclinD1 cell cycle pathway in the initiation
and progression of breast cancer. Similar results were obtained in animal assays. The data indicates that CDK2-AP1 can
induce sensitivity to docetaxel treatment in breast cancer cells.
Conclusions: CDK2-AP1 affects tumorigenesis, tumor growth and chemo-sensitivity by cell cycle regulation, which can
potentially to be a therapeutical agent in breast cancer.
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Despite encouraging advances in clinical and experimental
research, breast cancer ranks the first in the morbidity of
malignancies in women. Since 2008, the morbidity and
mortality of breast cancer have increased by 20 and 14%,
respectively. As estimated by World Health Organization* Correspondence: tigerzong@msn.com
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unless otherwise stated.(WHO), there were ~1.68 million new cases diagnosed
and 522,000 deaths due to breast cancer worldwide in
2012 [1]. Surgery and chemoradiotherapy are conven-
tional treatments, but they are not always satisfactory. Tar-
geting the estrogen/estrogen receptor pathway or the
human epidermal growth factor 2 (HER2) pathway now
shows promise in therapeutic strategies. However, both
have limitations in case selection, which may lead to poor
efficacy. Therefore, new targets and related molecular
markers need to be identified and urgently investigated.s an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cyclin-dependent kinases (CDKs), which are regulated
positively by cyclins and negatively by cyclin-dependent
kinase inhibitors (CKIs). When CDKs are abnormally up-
regulated, cells will always be undergoing cycles and may
acquire resistance to apoptosis, finally resulting in uncon-
trolled proliferation [2]. CDK2 is a member of CDKs
family that is important in malignant transformation of
human breast epithelial cells, probably by complexing
with cyclinD1 or with the assistance of low molecular
weight cyclinE [3-6]. Inhibition of CDK2 activity could
effectively restrain the proliferation of breast cancer cells
[7,8], including those resistant to endocrinotherapy [9].
Cyclin-dependent kinase 2 associate protein 1(CDK2-
AP1) is a specific negative regulatory protein for CDK2,
which is mainly responsible for degrading CDK2 and
interacting with DNA polymerase α to affect DNA repli-
cation of S-phase cells. The CDK-AP1 gene is a highly
conserved gene originating from normal keratinized epi-
thelium clones; it is located on chromosome 12q24.31
and has a full length of 1627 bp. It is also known to be
deleted in oral cancer-1(DOC-1) or P12, which is mainly
expressed in most human tissues, including breast, liver
and lung. Todd et al. [10] and Tsuji et al. [11] reported
that CDK2-AP1 may be an important tumor suppressor
in oral cancer because of its more frequent expression in
normal tissues than in oral cancer tissues [10,11]. This
speculation was confirmed by studies showing that
CDK2-AP1 can control the proliferation of oral cancer
cells in a TGF-β-dependent manner [12,13]. Kim et al.
[14] have also shown that CDK2-AP1 can promote
apoptosis of cancer cells by regulating CDK2 in cases
where chemotherapy has caused DNA damage, suggest-
ing a potential therapeutic role combined with DNA-
damaging agents (eg cisplatin) for oral/head and neck
cancers. In gastric cancer and esophageal cancer, loss of
CDK2-AP1 is closely correlated with malignant progres-
sion of cancer cells and a poor prognosis for patients
[15,16]. CDK2-AP1 also seems to have the potential to
control cancer cell growth and modify the functioning
of the androgen-responsive pathway, described by
Zolochevska et al. [17].
In spite of its important role in cancer suppression,
work on CDK2-AP1 in breast cancer is insufficient. Only
one single report had indicated that P12 can inhibit
growth of breast cancer cells in vivo and in vitro by
regulating the cell cycle [18]. However, either its role in
cell behavior or chemotherapeutic sensitivity of breast
cancer remains unclear. We have followed the expres-
sion of CDK2-AP1 and its related molecules (CDK2 and
CyclinD1) in normal human breast tissues and breast
cancers at different stages. We also did these assays
in vivo and in vitro to explore the specific roles of
CDK2-AP1 in breast cancer cells. The findings improveour understanding of the role of CDK2-AP1 in the de-
velopment of breast cancer and clarify the effect of
CDK2-AP1 in chemotherapy of breast cancer.
Materials and methods
Tissue specimens
For CDK2-AP1 expression analysis, samples including
normal breast tissue, DCIS, invasive breast cancer and
relapsed breast cancer from 209 patients were selected
randomly from Zhejiang Cancer Hospital from 2008 to
2011. None adjuvant chemoradiotherapies were adopted
before surgery. Informed consent for the research was
obtained from each patient. The Ethics Committee and
the Academic Committee of Zhejiang Cancer Hospital
approved this study.
Immunohistochemical staining
The paraffin blocks were cut into 5 μm sections and
mounted on slides. The sections were deparaffinized in
xylene and dehydrated with graded ethanol washes. The
slides were incubated with rabbit anti-human CDK2-
AP1/CDK2/CyclinD1 monoclonal antibody (Cat. #: 2910? 1,
1134 ? 1 and 1677 ? 1, Epitomics, Burlingame, CA) over-
night at 4?C. The slides were incubated with a biotinylated
goat anti-rabbit serum for 30 min and subsequently
reacted with a streptavidin-peroxidase conjugate and 3′,
3′-diaminobenzidine. Negative control was prepared using
the same procedure, except that normal rabbit IgG was
substituted for the primary anti-CDK2-AP1 antibody. The
staining intensities were classified into 2 groups: positive
(>80% of tumor cells were positively stained), negative
(<20%).
Cell culture
Human breast cancer cell lines MDA-MB-231, SK-BR-3
and MCF-7 were obtained from Chinese Academy of
Science Shanghai cell bank (Shanghai). The cells were
cultured at 37?C in 5% CO2/95% air in Dulbecco ? s Modi-
fied Eagle ? s Media (DMEM; Lonza) containing 10% FBS
(Lonza), 100 units/mL penicillin, and 100 μg/mL strepto-
mycin (Lonza). Parallel cell lines were treated with 50 μg/
ml epirubicin or 60 μg/ml docetaxel as contrast test.
Plasmid construction
The full length cDNA of CDK2-AP1 was amplified from
human brain library using the PCR method. CDK2-AP1
cDNA was inserted into the linearized vector pLV3
(Genechem). The products were transformed into bac-
terial competent cells. Positive colonies with inserted
fragments were confirmed by DNA sequencing to gener-
ate pLV3-CDK2-AP1 expression plasmid.
For RNA interference, 21-bp oligonucleotides en-
coding CDK2-AP1 (NM_004642) -specific siRNA were
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was 5′-GCTGCTGGCCATCATTGAAGA -3′, and the
non-silencing control was 5′-TTCTCCGAACGTGTCA
CGT -3′. siRNA oligos were annealed and ligated into the
BamH I/EcoR I-linearized pLV3 vector to generate CDK2-
AP1 shRNA and control shRNA expressing plasmids.
Lentivirus packaging
The recombinant lentiviral plasmids, the packaging vec-
tor pGag/Pol, pRev, and the envelope vector pVSV-G
were co-transfected into HEK293T cells using MISSION
Lentiviral Packaging Mix kit (Sigma-aldrich). The mix-
ture, including 20 μL Packing Mix (PVM), 12 μL PEI,
and 400 μL serum-free DMEM and 20 μg purified plas-
mid DNA, was incubated at room temperature for 15 min
and transferred to HEK293T cells at 70? 80% confluence.
The medium was replaced with fresh complete medium
after 16 h incubation, and the cells cultured for 48 h. The
supernatant were collected, purified, and concentrated
with a Centricon Plus-20 centrifugal ultrafiltration device
(Millipore).
Real-time RT-PCR
RNA was isolated using the TRIzol reagent (RNAiso;
Invitrogen). RNA was extracted with phenol-chloroform,
ethanol precipitated, and resuspended in diethyl pyrocar-
bonate? treated H2O. cDNA was prepared with a Reverse
Transcription kit (Promega) and subjected to quantitative
real-time PCR and reverse transcription PCR (RT-PCR).
Primer pairs for CDK2AP1 (GenBank,NM_004642)
were 5′-AGCATGGCAACGTC TTCACAGT-3′ and 5′-T
GGCATTCCGTTCCGTTTCT-3′. Primer pairs for CDK2
(GenBank, X61622) were 5′-TGGATGCCTCTGCTCTCA
CT-3′ and 5′-ATATTTCGAGCCCAGGAGGA-3′. Each
sample was processed in parallel with assays for GAPDH
(5′-ACCACAGTCCATGCCATCAC-3′, 5′-TCCACCACC
CTGT TGCTGTA-3′), and the absolute levels of each
mRNA were normalized relative to GAPDH.
One microliter template cDNA was used in a real-
time qPCR reaction with Kapa Sybr Fast Master Mix
(Applied Biosystems) and 10 pM each forward and reverse
primers for experimental or control genes. Polymerase
was activated at 95?C for 2 min, followed by 40 cycles of
denaturation at 95?C for 30 seconds, annealing at 60?C for
30 seconds, and extension at 60?C for 30 seconds, with
a final extension at 72?C for 5 min. Reactions were run
on a Step One Plus Real-time PCR System (Applied
Biosystems).
Western blot analysis
The protein concentration of the supernatants was de-
termined using the Bio-Rad DC protein assay system,
with BSA as standard. Equal amounts of protein (30 μg)
were run in 12% SDS-PAGE and transferring ontonitrocellulose membranes (Millipore). Membranes were
incubated with primary antibodies, washed, treated with
peroxidase-conjugated secondary antibodies, rewashed,
and the proteins visualized with enhanced chemilumin-
escence (ECL; Amersham, UK). Primary antibodies were
anti-CDK2-AP1, anti-CDK2, anti-CyclinD1 and anti-
GAPDH (BIOSS).
MTT assay
Cell growth and viability after lentivirus infection for
3 days were measured by the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide assay. Cells were
plated at 1 ? 10 3/well in 96-well plates, and theirl growth
measured after 48 h. Viable adherent cells were stained
with 20 μL MTT (5 mg/mL, Sigma-aldrich) for 4 h at
37?C. The medium was removed, and the formazan crys-
tals were dissolved in dimethyl sulfoxide. for measure-
ment of absorbance at 540 nm. Viability was expressed
as the ratio relative to untreated cells.
Colony formation assay
Lentivirus-infected cells in the logarithmic growth phase
were digested with trypsin and resuspended in complete
medium. One thousand cells/well were plated into 6-
well plates in triplicate, which were incubated until most
colonies contained >50 cells, with the medium being
changed every 3 days. The cells were washed with PBS,
and 1 mL paraformaldehyde added to each well for
30 min. They were washed with PBS and stained with
500 μL Giemsa dye for 20 min. The number of colonies in
each group was counted.
PI staining
Cell cycle distribution was analyzed by FACScan flow
cytometry (BD Bioscience). MCF-7 cells infected with
CDK2-AP1 overexpressing lentivirus were plated at 1 ?
106/well in 12-well plates.
After incubation for 24 h, cells were collected, washed
with PBS, and fixed with cold 70% ethanol. They were
treated with 1 unit DNase-free RNase and incubated for
30 min at 37?C. Propidium iodide (1 mg/mL; Sigma
Chemical) was added to the suspension, and a total of
20,000 cells were analyzed by FACScan.
Tumor formation in nude mice
Cloned pools of CDK2-AP1 interfected MCF-7 cells,
CDK2-AP1 overexpressed SK-BR-3 cells and control
cells were trypsinized and resuspended in PBS. One mil-
lion cells/mouse were injected into female athymic nude
mice (BALB/c-nu/nu) (n = 54, 20 ? 2 g, 4 ? 5 weeks old,
from Shanghai Slac Laboratory Animal Co, Ltd). The
mice were treated with saline, epirubicin or docetaxel,
10 mg/kg by tail vein injection each week. The protocol
Figure 1 Expression of CDK2-AP1 is reduced successively in normal bre
contrary to CDK2 and CyclinD1. A, The positive rates of CDK2-AP1 in no
cancer were 72.5, 16.7, 14.0 and 5.6%, respectively. Accordingly the positi
12.5, 50.0, 55.4 and 50%. B, Positive staining of CDK2-AP1 (?200) C, Positiv
Table 1 Expression of CDK2-AP1/ CDK2/ CyclinD1 in









CDK2-AP1 P 29 5 17 1 <0.001
N 11 25 104 17
CDK2 P 3 12 63 10 <0.001
N 37 18 59 8
CyclinD1 P 5 15 67 9 <0.001
N 35 15 54 9
Total 40 30 121 18
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mittee of Zhejiang Cancer Hospital.
Tumor size was recorded every 3 days with a precision
caliper as the maximum diameter (a, mm) and vertical
short diameter (b, mm). The volume was calculated using
the formula V (mm3) = 1/2ab2. The mice were killed
5 weeks after tumor cells injection and subcutaneous
tumor weight measured. Tumor were detected for bcl2/
bax and CDK2/ cyclinD1 using IHC.Statistical analysis
We used SPSS 19.0 software (IBM) for analysis. CDK2-
AP1 expression pattern was analyzed using Chi-square test.
Tumor weight and velocity was compared by general linear
regression for repeated measures. P < 0.05 was considered
a significant difference.ast tissue, DCIS, invasive breast cancer and relapsed breast cancer,
rmal breast tissue, DCIS, invasive breast cancer and relapsed breast
ve rates of CDK2 and CyclinD1 were 7.5, 40.0, 52.1and 55.6%; and
e staining of CDK2-AP1 (?200, in the nucleoli).
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CDK2-AP1 protein expression in normal and malignant
breast tissues and its correlation with CDK2 and CyclinD1
Expression of CDK2-AP1, CDK2 and CyclinD1 in 40
cases of normal breast tissues, 30 cases of ductal breast
cancer in situ, 121 cases of invasive breast cancer and 18
cases of relapsed breast cancer were examined by immu-
nohistochemical staining. CDK2-AP1 was expressed most
frequently in normal breast tissues, and least frequently in
metastasized breast cancer. Overall, the positive ratio of
expression of CDK2-AP1 was reduced successively in nor-
mal breast tissue, DCIS, invasive breast cancer and re-
lapsed breast cancer, in contrast to CDK2 and CyclinD1
expression (Table 1, Figure 1). CDK2-AP1 expression
seemed to be correlated closely with the malignant pro-
gression, from tumorigenesis to invasion and metastasis.
Therefore, CDK2-AP1 could act as a tumor suppressor
by inactivating CDK2/CyclinD1, and loss of CDK2-AP1
would be important in the initiation and development
of breast cancer.CDK2-AP1 expression knockdown in MCF-7 cells and
upregulation in SK-BR-3 cells
Expression of CDK2-AP1 mRNA was investigated by
real-time PCR analysis in MCF-7, SK-BR-3 and MDA-Figure 2 Expression of CDK2-AP1 mRNA and protein in three breast c
CDK2-AP1 expression at both mRNA and protein levels. In contrast, SK-BR-3
relatively high in MDA-MB-231 and MCF-7; lower in SK-BR-3. B, CDK2-AP1 p
blotting analysis.MB-231 cell lines (Figure 2A). CDK2-AP1 protein was
detected by Western blot assay (Figure 2B, 2C). MCF-7
cells have a relatively higher endogenous CDK2-AP1 ex-
pression, both in mRNA and protein. In contrast SK-BR-3
cells have lower CDK2-AP1 expression at both mRNA
and protein levels. Lentivirus-mediated CDK2-AP1 siRNA
was designed to knockdown endogenous CDK2-AP1 ex-
pression in MCF-7 cells (Figure 3A), real-time PCR ana-
lysis indicated a 80% reduction of its mRNA (Figure 3B).
The endogenous CDK2-AP1 protein level was reduced
78% (Figure 3D), and thus CDK2-AP1 RNAi lentivirus sig-
nificantly suppresses endogenous CDK2-AP1 expression.
A lentiviral expression vector was used to overexpress
CDK2-AP1 in SK-BR-3 cells to see its effectiveness as a
growth regulator (Figure 3A). CDK2-AP1 mRNA was up-
regulated 4.3-fold compared to control cells (Figure 3C),
consistent with protein expression (Figure 3E).CDK2-AP1 as a growth suppressor of breast cancer cells
MCF7/control and MCF7/ CDK2-AP1 RNAi cells were
seeded at low density (1 ? 10 3/well of 96-well plate), and
their growth rates measured by MTT assay. When CDK2-
AP1 was knockdown in MCF-7 cells, growth increased
by 1.3 fold in comparison with control group 48 h
later (Figure 4A). The colony number of MCF7 cellsancer cell lines. MCF-7 cells have relatively higher endogenous
cells have lower CDK2-AP1 expression. A, CDK2-AP1 mRNA level is
rotein level is higher in MCF-7; lower in SK-BR-3. C, Result of western
Figure 3 CDK2-AP1 was knocked down in MCF-7 cells and overexpressed in SK-BR-3 cells. A, CDK2-AP1 siRNA was transfected into MCF-7
cells and CDK2-AP1 overexpressed lentivirus vector was transfected into SK-BR-3 cells. B, CDK2-AP1 RNAi lentivirus infection results in 80.1% reduction
of CDK2-AP1 mRNA in RNA interfered MCF-7. C, CDK2-AP1 mRNA is upregulated 4.3-fold in CDK2-AP1 overexpressed SK-BR-3 cells compared
to the control cells. D, CDK2-AP1 protein level is reduced by 77.7% in interfected MCF-7 cells. E, CDK2-AP1 protein expression increases 4 fold
in overexpressed SK-BR-3.
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twice as high as the control group (Figure 4C).
Regarding the effect of CDK2-AP1 overexpression
in SK-BR-3 cells, MTT and colony formation assays
showed that it suppressed growth and colony forma-
tion (Figure 4B,C), both indicators of its growth sup-
pressor activity.CDK2-AP1 arrests cells in G0/G1 and G2/M phase
Overexpressed CDK2-AP1 arrested SK-BR-3 cells in
G0/G1 and G2/M phase (Figure 4D). The percentage of
G0/G1 phase cells increased from 68 to 77% (P < 0.05),
and G2/M phase from 14 to 14.5%, accompanied by a
fall of S phase cells from 17.6 to 8.5%. In contrast, inCDK2-AP1 silenced MCF-7 cells G0/G1 and G2/M
phase cells decreased from 78.9 to 67.7% and 9.06 to
8.01%, respectively, while S phase cells increased from
12,0 to 24.3%. Thus the CDK2-AP1 level is closely cor-
related with cell cycle progression.Inhibition of CDK2-AP1 in tumorigenesis of MCF-7 cells in
nude mice
To confirm that CDK2-AP1 can be involved in breast
cancer development, CDK2-AP1 silenced MCF-7 cells
and control cells were injected into nude mice subcuta-
neously and allowed to grow for 5 weeks. Inhibition of
CDK2-AP1 promoted tumor growth with a significant
increase in tumor size. Both the tumor volume and
Figure 4 CDK2-AP1 acts as a growth suppressor of breast cancer cells by arresting cells in G0/G1 and G2/M phase. Docetaxel sensitivity
is increased in breast cancer cells in the case of CDK2-AP1 expression. A, after CDK2-AP1 has been knockdown in MCF7 cells, viability was
increases by 1.31 fold compared with the control group. B, CDK2-AP1 overexpression suppresses the growth of SK-BR-3 cells. C, colony number of
MCF7 cells transfected with the CDK2-AP1 RNAi lentivirus is twice that of the control group, whereas for SK-BR-3 cells overexpressing CDK2-AP1 it is
reduced. D, overexpressed CDK2-AP1 arrests SK-BR-3 cells in G0/G1 and G2/M phase, whereas downregulated CDK2-AP1 promotes MCF-7 cells into
S phase.
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trols (Figure 5A,B). Immunohistochemistry suggested
that CDK2/ cyclinD1 expression and the ratio of
bcl2/bax also increased after inhibition of CDK2-AP1
(Figure 5C).Silencing CDK2-AP1 and resistance to docetaxel treatment
in breast cancer cells in vivo and vitro
To assess the effect of CDK2-AP1 as a potential che-
motherapeutic agent, drug sensitivity assays were run
both in vivo and in vitro (Figures 4A-C and 5D). After
Figure 5 Loss of CDK2-AP1 promotes tumorigenesis of MCF-7 cells in nude mice, inhibits tumor apoptosis, and lowers sensitivity to
docetaxel. A, inhibition of CDK2-AP1 results in a significant increase in tumor size (p < 0.05). B, tumor volumes increase compared to the controls
(p < 0.05). C, expression of CDK2/ cyclinD1 and the ratio of bcl2/ bax both increase after inhibition of CDK2-AP1 according to the result of IHC.
D, CDK2-AP1 silenced MCF-7, MCF-7 and CDK2-AP1 overexpressed SK-BR-3 cells have been used in the drug sensitivity experiments, docetaxel
sensitivity was increased in the case of CDK2-AP1 expression, whereas silencing CDK2-AP1 induces resistance to treatment in breast cancer
(p < 0.05). Expression of CDK2-AP1 had little influence on epirubicin sensitivity.
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proved less sensitive to docetaxel treatment, having
a higher cell proliferation rate than the controls.
After treatment with epirubicin, however, no signifi-
cant difference between the two groups in terms of
cell proliferation were seen, a result confirmed by
bearing-tumor nude mice assay. Thus CDK2-AP1 could
enhance the sensitivity of docetaxel treatment in breast
cancer cells.Discussion
CDK2-AP1 is a direct upstream of CDK2, which can
induce cell apoptosis by inactivating CDK2. On losing
it CDK2-AP1, an activated downstream signal pro-
motes excessive proliferation of normal cells, which
may lead to malignant transformation of normal cells.
In cancer, however, loss of CDK2-AP1 could increase
proliferation and invasiveness to cancer cells. By immu-
nohistochemistry, the expression of CDK2-AP1 was found
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invasive breast cancer and metastasized breast cancer.
The expression of CDK2-AP1 was also negatively corre-
lated with the expression of CDK2 and cyclin D1. We de-
duced from this that loss of CDK2-AP1 is important in
the development of breast cancer; loss of CDK2-AP1
might promote the progression of breast cancer through
altered downstream cell cycle-related molecules.
Loss-of-function and gain-of-function assays helped as-
sess the specific role of CDK2-AP1 in breast cancer. After
downregulating CDK2-AP1 in breast cancer cells, cell
proliferation rate increased, whereas after upregulating
CDK2-AP1, there was arrest in G0/G1 phase and G2/M
phase and therefore inhibited proliferation. To find
whether these changes were due to the regulation of
CDK2-AP1 in CDK2-AP1/CDK2/CyclinD1 pathway, we
looked at the expression of CDK2 and CyclinD1. Both
were changed accordingly after downregulating or up-
regulating CDK2-AP1, which indicates a possible role
of the CDK2-AP1/CDK2/CyclinD1 cell cycle pathway
in the initiation and progression of breast cancer. This
was confirmed by animal assays which showed that: 1) a
CDK2-AP1 silenced group was more tumorigenic and had
a faster growth rate of tumor than the controls; 2) higher
expression of CDK2 and CyclinD1 was seen, accompanied
by a higher ratio of bcl2/bax in the CDK2-AP1 silenced
group than in the control group. These results imply
the following: loss of CDK2-AP1 activates CDK2 and
CyclinD1 continuously, which in turn increases the ra-
tio of bcl2/bax probably by upregulating bcl2, which fi-
nally enhances resistance to apoptosis in the cancer
cells. In conclusion, the findings offer evidence that loss
of CDK2-AP1 promotes the initiation and progression
of breast cancer by its effects on the cell cycle.
We also assayed in vivo and in vitro the impact of
CDK2-AP1 on chemotherapeutic sensitivity in breast
cancer. After treating cancer cells with docetaxel, the
CDK2-AP1- silenced group had a faster rate of cell pro-
liferation and tumor growth than the control group,
suggesting that CDK2-AP1 enhances the sensitivity.
However, cancer cells treated with epirubicin showed
no such difference. We surmise that epirubicin works
as a non-specific cell-cycle agent which could disturb
transcription and inhibit the synthesis of DNA and
RNA by being directly inserted into DNA base-pairs.
Thus, it is to be expected that a CDK2-AP1 activated
cell cycle pathway has little effect on epirubicin treat-
ment. Notably, the anti-tumor effect of docetaxel is
mainly based on its suppression of cell division and
proliferation by inducing tubulin polymerization, which
prevents spindle formation during mitosis. Therefore,
by its differential effects on the phases of cell cycle,
CDK2-AP1 induces sensitivity to docetaxel treatment
in breast cancer cells.In summary, abnormal CDK2-AP1 expression is asso-
ciated with the development and progression of breast
cancer. It also acts on the sensitivity to docetaxel in
breast cancer. Although the functions of CDK2-AP1 in
cancer are not yet fully understood, these new insight
into CDK2-AP1 in the biology and treatment of breast
cancer should help. CDK2-AP1 has potential value as a
new agent for the prevention and therapy of breast
cancer.
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